Patents by Inventor Olaf Merkel

Olaf Merkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Highly phosphorylated and sulfated recombinant factor IX
    Patent number: 7575897
    Abstract: The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: August 18, 2009
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Friedrich Scheiflinger, Ernst Boehm, Michele Himmelspach, Olaf Merkel
  • HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX
    Publication number: 20080176287
    Abstract: The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.
    Type: Application
    Filed: March 28, 2008
    Publication date: July 24, 2008
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Friedrich Scheiflinger, Ernst Boehm, Michele Himmelspach, Olaf Merkel
  • Highly phosphorylated and sulfated recombinant factor IX
    Patent number: 7375084
    Abstract: The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: May 20, 2008
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Friedrich Scheiflinger, Ernst Boehm, Michele Himmelspach, Olaf Merkel
  • HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX
    Publication number: 20070244036
    Abstract: The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.
    Type: Application
    Filed: March 7, 2007
    Publication date: October 18, 2007
    Applicants: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Ernst Boehm, Michele Himmelspach, Olaf Merkel